These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25107641)

  • 61. Practical Approach to Triple-Negative Breast Cancer.
    Gadi VK; Davidson NE
    J Oncol Pract; 2017 May; 13(5):293-300. PubMed ID: 28489980
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The proteomic landscape of triple-negative breast cancer.
    Lawrence RT; Perez EM; Hernández D; Miller CP; Haas KM; Irie HY; Lee SI; Blau CA; Villén J
    Cell Rep; 2015 Apr; 11(4):630-44. PubMed ID: 25892236
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Robust identification of target genes and outliers in triple-negative breast cancer data.
    Segaert P; Lopes MB; Casimiro S; Vinga S; Rousseeuw PJ
    Stat Methods Med Res; 2019; 28(10-11):3042-3056. PubMed ID: 30146936
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells.
    Kong X; Ding X; Yang Q
    Int J Oncol; 2015 May; 46(5):2047-56. PubMed ID: 25826742
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Spatiotemporal quantitative microRNA-155 imaging reports immune-mediated changes in a triple-negative breast cancer model.
    Skourti E; Volpe A; Lang C; Johnson P; Panagaki F; Fruhwirth GO
    Front Immunol; 2023; 14():1180233. PubMed ID: 37359535
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multi-agent System for Obtaining Relevant Genes in Expression Analysis between Young and Older Women with Triple Negative Breast Cancer.
    González-Briones A; Ramos J; De Paz JF; Corchado JM
    J Integr Bioinform; 2015 Oct; 12(4):278. PubMed ID: 26673929
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Response.
    Liu NQ; Smid M; Martens JW; Foekens JA; Umar A
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265942
    [No Abstract]   [Full Text] [Related]  

  • 68. Lack of epidermal growth factor receptor (EGFR)-activating mutations in triple-negative breast cancer in China.
    Cao WM; Gao Y; Wang XJ
    Breast Cancer Res; 2015 Aug; 17(1):115. PubMed ID: 26290189
    [No Abstract]   [Full Text] [Related]  

  • 69. Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer.
    Athreya AP; Gaglio AJ; Cairns J; Kalari KR; Weinshilboum RM; Wang L; Kalbarczyk ZT; Iyer RK
    IEEE Trans Nanobioscience; 2018 Jul; 17(3):251-259. PubMed ID: 29994716
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No driver behind the wheel? Targeting transcription in cancer.
    Franco HL; Kraus WL
    Cell; 2015 Sep; 163(1):28-30. PubMed ID: 26406367
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Subtyping of triple-negative breast cancer.
    Mayer IA
    Clin Adv Hematol Oncol; 2013 Nov; 11(11):731-2. PubMed ID: 24896546
    [No Abstract]   [Full Text] [Related]  

  • 72. Metabolic Reprogramming in Triple-Negative Breast Cancer.
    Sun X; Wang M; Wang M; Yu X; Guo J; Sun T; Li X; Yao L; Dong H; Xu Y
    Front Oncol; 2020; 10():428. PubMed ID: 32296646
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Asporin: the protective wall against triple-negative breast cancer].
    Blomme A; Cusumano P; Peulen O; Bellahcène A; Castronovo V; Turtoi A
    Med Sci (Paris); 2016 Nov; 32(11):1019-1022. PubMed ID: 28008845
    [No Abstract]   [Full Text] [Related]  

  • 74. Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates.
    Lastraioli E
    Front Pharmacol; 2020; 11():725. PubMed ID: 32508650
    [TBL] [Abstract][Full Text] [Related]  

  • 75. New targets in triple-negative breast cancer.
    Copeland RL; Kanaan Y
    Nat Rev Cancer; 2021 Dec; 21(12):744. PubMed ID: 34621048
    [No Abstract]   [Full Text] [Related]  

  • 76. Comment on 'Circulating cell-free miRNAs as biomarker for triple-negative breast cancer'-Methodological challenges in combining miRNAs as circulating biomarkers.
    Verderio P; Bottelli S; Lecchi M; Plebani M; Gariboldi M; Pizzamiglio S; Ciniselli CM
    Br J Cancer; 2016 May; 114(10):e5. PubMed ID: 27100729
    [No Abstract]   [Full Text] [Related]  

  • 77. Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer.
    Zhao W; Liu J; Li Y; Chen Z; Qi D; Zhang Z
    Front Pharmacol; 2021; 12():731741. PubMed ID: 34925002
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis.
    Rong G; Yi Z; Ma F; Guan Y; Xu Y; Li L; Xu B
    Cancer Commun (Lond); 2020 Dec; 40(12):738-742. PubMed ID: 33009697
    [No Abstract]   [Full Text] [Related]  

  • 79. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
    Dai X; Xiang L; Li T; Bai Z
    J Cancer; 2016; 7(10):1281-94. PubMed ID: 27390604
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Frequency of MicroRNA Response Elements Identifies Pathologically Relevant Signaling Pathways in Triple-Negative Breast Cancer.
    Nair AA; Tang X; Thompson KJ; Vedell PT; Kalari KR; Subramanian S
    iScience; 2020 Jun; 23(6):101249. PubMed ID: 32629614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.